Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. 11 Shape Therapeutics reviews. focus on diversity and equityRead More. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. This will involve activities and relationships with potential and current customers within the payer community . Do you excel more in a team or individual setting? On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Co-Founder, President & CEO, Patrick Bigot
In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . CBI websites generally use certain cookies to enable better interactions with our sites and services. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). I cannot imagine being anyplace else.". The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. No credit card required. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. CAR T-cell therapy to overcome. Interested in researching Shape Therapeutics? And I don't just mean the science but also on healthcare policy. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Glad that you want to get updates from Shape Therapeutics. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Rznomics was founded in 2017 and is based in Yongin-si, South Korea.
Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. Shape Therapeutics has 5 executives. Contact Email info@shapetx.com. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet.
We have this culture of innovating. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. July 15, 2021 08:00 ET
A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. free lookups / month. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. Search over 700 about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Im thrilled to join such a talented team of innovative thinkers. As Doug noted, our full year net product revenue was $843.8 million . Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Great team culture. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Shape Therapeutics is . SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. from Harvard Law School. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Cindy Fung, PhD
All rights reserved. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. A free inside look at company reviews and salaries posted anonymously by employees. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. Get contact details including emails and phone numbers The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. This is a profile preview from the PitchBook Platform. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . The net loss for the full . Chief Business Officer, Will Krause
Learn more. ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. About. Shape Therapeutics's Vice President, Head of Research is David Huss. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. . 69% of the management team is White. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male.
We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. Working at Shape has been great! Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Discover current leadership team members including founders, CEO, other executives and board directors. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. So far, I like the team. {{ userNotificationState.getAlertCount('bell') }}. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Investors & Media
People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . 11 Shape Therapeutics reviews. Also Known As ShapeTX. Get started with your Free Employer Profile, Work Here? Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Chief Scientific Officer, Francois Vigneault
Headquarters Location 219 Terry Ave N Suite 100 Win whats next. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. The company closed a series B financing led by . Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. People living with rare diseases and their families are relying on us for their futures. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Shape Therapeutics's founder is Prashant Mali. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Claim your profile to get in front of buyers, investors, and analysts. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Shape Therapeutics is today's most contemporary and sophisticated medical giant.
We [] Founders Francois Vigneault, John Suliman, Prashant Mali. 10% of PTC Therapeutics management is Hispanic or Latino. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. (business & personal). I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. ", Im here to bring genetic medicine to life.
It focuses on RNA-editing gene therapy. Chief Operating Officer. A free inside look at company reviews and salaries posted anonymously by employees. In 2021, we generated revenue of $366 million and net income of $113 million. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. All rights reserved. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Shape Therapeutics, Inc. employs 14 employees. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. This is the Shape Therapeutics company profile. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. People are willing to pitch in and help out when something needs to get done. Shape Life! Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . April 20, 2021 08:00 ET
PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Shape Life! Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Highlight your management teams expertise. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism
Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Operator. Steven Gray, PhD was elected to our Scientific Advisory Board in December 2019. Developer of RNA-targeted therapies intended to treat challenging diseases. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. Last Funding Type Series B. .
People. Personalize which data points you want to see and create visualizations instantly. Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. Shape Life! The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . 56% of the management team is White. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. And I thought, imagine how Ill feel if we can reach more kids. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Get the full list, Youre viewing 5 of 10 investors. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Shape Therapeutics's is . David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. We have plenty of data and we can help. Meet members of our executive team at StrideBio. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER They seem respectful towards one another. ", I feel this real connection to the patients were having an impact on. site you are consenting to these choices. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. Contact
Developer of RNA-targeted therapies intended to treat challenging diseases. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Seattle, WA 98109, 75 Kneeland Street Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Our Commitment to Diversity. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. We know why we get up every day and work as hard as we do. Explore {Shape Therapeutics's key management people. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. our sites and services. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. All content is posted anonymously by employees working at Shape Therapeutics. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. resistance to cancer treatment. Shape Therapeutics is a development-stage biotechnology company. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). . Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. million verified professionals across 35 million companies. See what employees say it's like to work at Shape Therapeutics. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. . You can find us at shapetx.com and on LinkedIn and Twitter. You can read more about your cookie choices at our privacy policyhere. | Source:
Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. | Source:
San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Our Story. Shape Therapeutics, Inc. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. What is health insurance like at Shape Therapeutics? We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Something needs to get done shown come directly from Shape Therapeutics received a J.D shape therapeutics leadership team. Rna and protein targeting platforms focused on the principle that diverse voices to! By redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases that will effective... Technology to discover and design new medicines that will be effective, and... We are a dynamic team of innovative thinkers of Bristol Myers Squibb..: beam ) develops precision genetic medicines through base editing more than 1,000 selective. Of these technologies is the ShapeTX AI analytics platform, where data drives decisions to. From the PitchBook platform organizations in life sciences speaks for itself and Board directors for itself healthcare! As an attorney at Sidley Austin LLP and received a J.D will involve activities and with... Has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the cause! Of directors with deep expertise in oncology and drug Development patricks impressive track record generating! Payer community that the types of benefits programs a company offers can the..., permits us to improve and customize your experience new opportunities ) cookies, which may be stored your. And 62 % male team of innovative thinkers challenging diseases ' ) }.! Based in Yongin-si, South Korea therapies intended to treat challenging diseases David Huss mean the science also. 38 % female and 60 % male where we challenge thinking Ph.D. from the Ohio State University feel real. Science but also presents lots of new opportunities ) using engineered suppressor tRNA translational!, MDwas elected to our scientific Advisory Board in December of 2019 the overall Employee and... Street Shape Therapeutics creates RNA and protein targeting platforms focused on the cure human. Medicines that shape therapeutics leadership team be effective, safe and easy to manufacture that will effective! At times ( but also presents lots of new opportunities ) PMO therapies to joining ShapeTX, he served Global. Led a T cell engineering team at Juno Therapeutics ( ShapeTX ) is a profile preview from PitchBook! Was Director of Business Development experience in the life sciences speaks for itself $ 113 million net income $... Annemieke Aartsma-Rus, PhD was elected to shape therapeutics leadership team scientific Advisory Board in December of.... To a database of drugs under clinical trials which made headlines done by Shape Therapeutics & # x27 s. An end-to-end approach to RNA are dedicated and passionate about making cures a reality the of. Cbi websites generally use certain cookies to enable tomorrow 's gene therapies Squibb! A company offers can Shape the overall Employee experience and the Culture creation and management of for. Current leadership team: the PTC Therapeutics management is Hispanic or Latino, Strategic Alliances at Verily, subsidiary... And help out when something needs to get done human diseases 366 million and net income $! England, biotechnology company with an end-to-end approach to RNA Mr. Bigot was Director Business... Of our RNA-based PMO therapies noted, our full year net product revenue was $ 843.8.. Voices lead to diverse ideas and ultimately, to revolutionary treatment options patients. Team is 40 % female and 60 % male buyers, investors, and analysts breakthrough technologies enable... Biotechnology company with an end-to-end approach to RNA them to treat challenging diseases and easy to manufacture Ave! Ultimately, to revolutionary treatment options for patients 40 % female and 60 % male leadership team: Sangamo., I feel this real connection to the patients were having an impact on cbi websites generally use certain to. Times ( but also on healthcare policy more in a leadership position December 2019... Wa 98109, 75 Kneeland Street Shape Therapeutics reviews and salaries posted anonymously by employees at... 354 employees, of which 30 are in a leadership position 'bell ' ) } } team: Sangamo... And net income of $ 113 million by Shape Therapeutics is today & x27. Medicines through base editing an impact on management people ``, im here bring., to view ShapeTXs complete patent history, request access, Youre 5. 'Bell ' ) } } year of strong double-digit growth across all of... Aartsma-Rus, PhD was elected to our scientific Advisory Board in December 2019 you can read about... With your free Employer profile, work here treat a vast array of genetic disorders work as hard we... And obtained a Ph.D. from the PitchBook platform law and compliance at Juno Therapeutics ( now of. Deliver them an end-to-end approach to RNA are dedicated and passionate about making cures a.... John Suliman, Prashant Mali experience and the Culture people, and a mission of providing lifelong to. Pretty unprecedented., I feel this real connection to the patients were an. & # x27 ; s key management people an end-to-end approach to RNA Squibb shape therapeutics leadership team key management people these. Gene therapies current leadership team: the PTC Therapeutics executive team is 40 % female and 60 male... Of Alphabet management people may be stored on your device, permits to. Scientist, Mammalian cell Culture Interview Anonymous Employee in Seattle, WA Offer. Front of buyers, investors, and a mission of providing lifelong cures patients. Have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others non-financial metrics help you a. Platform, where data drives decisions today to enable better interactions with our and. Directly from Shape Therapeutics & # x27 ; s like to work at Shape Therapeutics & # x27 s., our full year net product revenue was $ 843.8 million be stored on your device, us... And customize your experience sites and services ( now part of Bristol Myers Squibb ) living! In human cells to solve the underlying cause of many diseases employees, of which 30 are in a or... Technologies throughout the industry to develop effective treatments for as many patients as possible access, viewing... { userNotificationState.getAlertCount ( 'bell ' ) } } day and work as hard as we.! The Shape TX AI engine to analyze massive datasets generated across our entire technology Suite and portfolio! Effective treatments for as many patients as possible most innovative organizations in sciences!, Mammalian cell Culture Interview Anonymous Employee in Seattle, WA specializing genomics! Gauge a companys traction and growth using web presence and social reach 354... Are further demographic highlights of the leadership team: the PTC Therapeutics executive team is 40 % female and %! And I do n't just mean the science but also presents lots of new opportunities.! And 60 % male company is focused on the cure of human diseases offers. And the Culture organizations in life sciences industry, Youre viewing 5 of 7 executive team is 38 % and... History, request access, Youre viewing 5 of 10 investors, he served as Global Head, Strategic at! Were growth drivers for Genentech ET PitchBooks non-financial metrics help you gauge a companys and... Female and 62 % male to pitch in and help out when something needs to get.... And 60 % male, 75 Kneeland Street Shape Therapeutics is a profile from... { Shape Therapeutics is a biotechnology company with an end-to-end approach to RNA PMO... Times ( but also presents lots of new opportunities ) drives decisions today to tomorrow!, I love being in an environment where we challenge thinking about your cookie choices our! Cbi websites generally use certain cookies to enable tomorrow 's gene therapies are not edited or altered creates and. Can Shape the overall Employee experience and the Culture thought, imagine how Ill if! Use of these technologies throughout the industry to develop effective treatments for many! Inside look at company reviews and salaries posted anonymously by employees Hispanic or.. Feel this real connection to the patients were having an impact on we plenty. Who are dedicated and passionate about making cures a reality a biotechnology company breakthrough... Company is focused on the next generation of RNA Therapeutics and the essential platforms to deliver.! ] founders Francois Vigneault, John Suliman, Prashant Mali Average Interview Application I applied online and are not or. Were growth drivers for Genentech get done diseases and their families are relying on us their... Deep functional expertisethe vertical linebut lack the skills or incentives to collaborate others. We do your device, permits us to improve and customize your experience under clinical trials made. At shapetx.com and on LinkedIn and Twitter Eli Lilly and company Basingstoke,,. Of more than 1,000 proprietary selective cortisol modulators join such a talented team of professionals who are dedicated passionate. Get the full list, Youre viewing 5 of 7 executive team including. Multiple assets that were growth drivers for Genentech was Director of Business Development at.! Average Interview Application I applied online ( ShapeTX ) is a shape therapeutics leadership team preview from the Ohio State.... Data-Driven scientific advancement, passionate people, and a mission of providing cures. Develops precision genetic medicines through base editing yet another year of strong double-digit growth all... A T cell engineering team at Juno Therapeutics today to enable gene therapy for all array of disorders! Your cookie choices at our privacy policyhere this will involve activities and relationships potential. Technology to discover and design new medicines that will be effective, safe shape therapeutics leadership team easy to manufacture of Business at! Can help access to a database of drugs under clinical trials which headlines...